News
Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch - offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize at the...
read more
Minomic secures key patent in the United States and China
Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology company specializing in the...
read more
Minomic announces completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
No drug-related adverse effects found in patients Sydney, Australia, 24th July 2018: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder and pancreas. The Company...
read more
Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
58% Fewer patients proceed to Biopsy. US Rollout well advanced. May 17, 2018: [Sydney] Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer...
read more
ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial
A poster with headline results of the MiCheck-01 prospective trial was presented by Dr Brad Walsh, Minomic’s CEO at ASCO GU Cancers Symposium 2018 on 8 February. The 350-patient study highlights the test’s performance in differentiating aggressive from non-aggressive...
read more
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...
read more
Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access July 18, 2017: [Sydney] Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US...
read more
Minomic clinical study progresses for Miltuximab® in prostate, bladder, and pancreatic cancer
June 27, 2017: [Sydney] Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of Miltuximab®, a chimeric version of Minomic’s MIL-38 anti-Glypican-1 antibody conjugated to the radioactive...
read more
Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers
No Adverse Effects Found in Patients Dosed To-Date Sydney, Australia, 5 January 2017: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder, and pancreas. The...
read more
Minomic launches first-in-human clinical trial of radioactive anti-cancer antibody
Media Release Immunotherapy targets prostate, bladder, pancreatic cancer First of 12 patients enrolled in clinical trial Treatment scheduled to begin within days Sydney, Australia, 22 August 2016: Immuno-oncology company, Minomic International, has enrolled the first...
read more